32 results about "Lethal toxin" patented technology

A phospholipase A2 inhibitor protein designated “Phospholipase Inhibitor from Python” (PIP)—formerly designated “Python Antitoxic Factor” (PAF)—is given by SEQ ID NO:2. The partial amino acid sequence for PIP was initially determined from the native protein purified from the blood serum of a non-venomous snake, Python reticulatus. The complete PIP polynucleotide sequence was obtained from a cDNA clone encoding PIP, given by SEQ ID NO:1, along with the full amino acid sequence deduced from it. Also disclosed is a recombinant protein PIP, which shows strong lethal toxin neutralizing activity similar to the native PIP, and has potent anti-inflammatory activity. Both the native and the functionally equivalent recombinant PIP are useful for the prevention or treatment of conditions such as snakebites, insect stings, and inflammatory diseases. Also, phospholipase A2 (PLA2) inhibitory polypeptides designated P-0029, P-0009, and P-0006, the sequences of which are given as SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12, respectively, are disclosed. Those polypeptides, and their synthetic chemical analogues and polypeptide variants that inhibit PLA2 activity and alleviate inflammation, may also be used in the diagnosis, study, prevention, and treatment of PLA2-related human inflammatory diseases.

The invention provides a genetic engineering bivalent (rPA+rLF) anthrax vaccine.Active ingredients of the bivalent anthrax vaccine include R178A / K197A mutant protein rPA of anthrax protective antigen and R491A / L514A mutant protein rLF of a lethal factor.The vaccine is prepared from the protective antigen PA and lethal factor LF dominant biological inactivation mutant protein, the advantages are that the protective antigen PA and lethal factor LF cannot be combined, capacity of generating anthrax toxin of a natural composition and action of lethal toxicity are lost, the immunogenicity and protectiveness of the dominant biological inactivation mutant protein rPA are superior to wild protective antigen PA, and the dominant biological inactivation mutant protein rLF can stimulate an organism to increase the immune protective effect; therefore, by means of the bivalent genetic engineering vaccine, the protection effect of the mutant protein rPA is greatly enhanced, five times or more of lethal dose of the lethal toxin can be resisted to, meanwhile the biologically inactivated rPA and rLF can further compete for combining with a receptor to inhibit activity of wild toxin, the purpose of neutralizing anthrax toxin is achieved, and it is inspected to achieve a good protection effect on inhaled infection anthrax.